IMFINZI 50 mg/mL concentrate for solution for infusion., CAPECITABINE , TREMELIMUMAB clinical trials

ADJUBIL - A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJUvant situation for BILiary tract cancer

This study is looking at new treatments for a type of cancer called biliary tract cancer after surgery. It combines existing cancer drugs with new immunotherapy drugs, durvalumab and tremelimumab. The aim is to see if these combinations can stop the cancer from coming back and improve how long people live well.